Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of VC004 in advanced or metastatic solid tumors, focused on NTRK fusion-positive tumors
CTR20201703Phase 2Active
- Sponsor
- Wecare Probiotics
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eratrectinib in Nonhematologic neoplasms, NTRK fusion-positive solid tumor, sponsored by Wecare Probiotics. Started Dec 2020; status: active.
02
Drugs
eratrectinib
03
Conditions
Nonhematologic neoplasmsNTRK fusion-positive solid tumor
Beyond the preview
Go deeper on CTR20201703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201703.